Regeneron Pharmaceuticals - Largest Companies by Marketcap, Revenue, Net Income and Employees
Top Corporates Hub
Regeneron Pharmaceuticals
REGN
|
NASDAQ
|
United States
235
-107
Rank
$115.11B
Market Cap
$14.20B
+$ 1.09B
+8.31%
Revenue
$4.77B
+$ 0.12B
+2.58%
Earnings
15.2K
+1.7K
+12.7%
Employees
About
Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
- Sector: Health Technology
- Industry: Pharmaceuticals: Major
- Headquarters:
Latest News
-
AstraZeneca’s gMG drug fails to fend off rivals despite Phase III win
31.10.2025 -
Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award
31.10.2025 -
JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential
31.10.2025 -
Opko Health Inc.’s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals
31.10.2025 -
What Catalysts Are Driving the Changing Narrative for Regeneron?
30.10.2025